CAPR earnings date and last-quarter result: next report 2026-08-11, last quarter miss, P/E -8.15. Updated 2026-07-23.
Capricor Therapeutics (CAPR) Research Hub
Capricor Therapeutics (CAPR) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 5.74 USD (-3.20%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -8.15, market cap 0.88B. This hub links to the full technical, earnings and options research available for CAPR.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 5.74 USD (-3.20%) |
| 52-week range | 2.96 USD – 30.19 USD |
| Trend regime | Range |
| 14-day RSI | 28 (Oversold) |
| Trailing P/E | -8.15 |
| Market cap | 0.88B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for CAPR
Covered Call on CAPR: how it works, illustrative setup around the real 5.74 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CAPR: how it works, illustrative setup around the real 5.74 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CAPR: how it works, illustrative setup around the real 5.74 USD price, max profit/loss, breakeven and when to use it. Educational.
CAPR technical analysis: range, last 5.74 USD, RSI 28, 52w range 2.96 USD–30.19 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is CAPR in?
Capricor Therapeutics (CAPR) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CAPR in an uptrend or downtrend?
As of 2026-10-26, CAPR is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CAPR's trailing P/E ratio?
CAPR's trailing P/E is -8.15, with a market cap of 0.88B. See the earnings research page for full valuation detail.
When does CAPR next report earnings?
CAPR is next scheduled to report earnings on 2026-08-11.